



Missouri Board of Pharmacy

PO Box 625, Jefferson City, MO 65102
 Web site: <http://pr.mo.gov/pharmacists.asp>

Published to promote voluntary compliance of pharmacy and drug law.

New Board Members

Governor Matt Blunt made the following appointments to the Missouri Board of Pharmacy: James D. Riddle, RPh, owner, Plaza Pharmacy, Shell Knob, MO, replaces Timothy Koch, RPh, who relocated out of the state. Barbara A. Bilek, PharmD, pharmacy director, Heartland Regional Medical Center, St Joseph, MO, replaces Douglas Lang, RPh, whose term expired April 2007. Congratulations to the new members and thanks to the outgoing members for their years of service to the Board.

New Inspectors

The Board welcomes two new inspectors to the Board staff. George McConnell, RPh, Joplin, MO, is responsible for the Southwest area of the state and Shawn Marshall, RPh, Sibley, MO, is responsible for a newly created West-Central area of the state. Mr McConnell joins the Board staff having practiced hospital pharmacy for over 20 years. He also has experience in chain retail pharmacy and long-term care practice settings. Ms Marshall has practiced as pharmacist-in-charge and staff pharmacist for Walgreen Co since 1995 and also holds a degree in justice studies. The creation of a new territory modifies existing inspector territories and may assign a new inspector to your area. Please refer to the Board Web site at <http://pr.mo.gov/pharmacists.asp> for updated county listings and inspector contact information.

Gold Certificates

The following pharmacists will receive gold certificates in honor of maintaining a license with the Board for 50 years. Each gold certificate is signed by Board members, the executive director, and Governor Matt Blunt and is accompanied by a letter of congratulations from the Board. Congratulations to those who have served the public for 50 years as a licensed pharmacist.

- Frederick V. Behm – Affton, MO
- Jerold W. Boss – St Louis, MO
- Roger F. Bruner – Webb City, MO
- Lee R. Bruner – Springfield, MO
- Donald D. Burgess – O’Fallon, MO
- Conchita Dominguez – St Louis, MO
- Edward L. Goldenhersh – Los Angeles, CA
- Stanley J. Heller – Chesterfield, MO
- Leonard J. Kaemmerer – Florissant, MO
- Victor J. Kintz – St Louis, MO
- Pierre A. Nessing – Florissant, MO
- Jordan Ollanik – Tuscon, AZ
- Richard P. Schneider – St Charles, MO
- Stanley L. Schneiderman – Chesterfield, MO

- J. Shark – Florissant, MO
- George E. Simms – Kansas City, KS
- William M. Smith – San Antonio, TX
- Alvin O. Tockstein – Belleville, IL
- Frank E. Vanbreusegen – St Louis, MO
- William R. Vetter – St Louis, MO
- Raymond E. Wahlbrink – Louisville, KY
- Robert E. Walters – St Peters, MO
- Daniel R. Wiegand – Edwardsville, IL
- Everett W. Winch – Independence, MO

Board of Pharmacy Licensing Statistics

The Missouri Board of Pharmacy currently licenses/registers a total of 27,064 individuals and businesses. This is an increase of 2,008 compared to the 2006 report. The following provides a breakdown for each category of license/registration.

Category	Total number	Change from previous year
Pharmacies	1830	+67
Pharmacists (7,549 active, 233 inactive)	7,782	+77
Interns	1,367	+231
Technicians	14,731	+1,543
Drug Distributors	1,254	+82
Drug Distributor Registrants	100	+8

Continuing Education Requirement

For the upcoming 2008 pharmacist license renewal, continuing education credits must be earned between **September 1, 2006 and August 31, 2008**. Credit earned prior to or after this date range will not be accepted towards the renewal of pharmacist licenses.

Licensing Action Report Pharmacists

Derk C. Gavan #040988, Jefferson City, MO. June 11, 2007. Pharmacist license revoked, cannot reapply for seven (7) years. Violation of previous disciplinary order. Failed to attend approved counseling, failed to provide a copy of his settlement agreement to employers within five business days, did not abstain from controlled substances unless prescribed by a

Continued on page 4



manufacturers place the small, translucent caps on parenteral syringes packaged without needles as a protective cover. However, practitioners may not realize the cap is there or may not inform patients or caregivers of the need for its removal prior to use. The danger arises due to the fact that the cap does not provide a good seal. Subsequently, medications can be drawn into many of these syringes without removing the caps. If not removed before administration, the force of pushing the plunger can eject the cap and cause it to lodge in a child's trachea.

Safe practice recommendations: Consider the following strategies to help protect your patients from tragedies caused by syringe tip caps.

- ◆ **Increase awareness.** Share this and previous errors with staff to illustrate why parenteral syringes should never be used for oral liquid medications. Show staff a video from FDA and ISMP highlighting this issue (access the video link at: www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=3#6).
- ◆ **Product availability.** Ensure that oral syringes (without caps) or other appropriate measuring devices are readily available for distribution or purchase at your practice site. Verify that the dosage can be accurately measured using the oral syringe. It may be necessary to keep a few different sizes on hand to ensure proper measurement of smaller doses.
- ◆ **Limit access.** If parenteral syringes must be stocked for use with injectable products, purchase syringes that are not packaged with the translucent caps to minimize the likelihood of this error.
- ◆ **Warning labels.** Add warning labels that state, "not for use with oral liquids" to boxes or storage bins containing parenteral syringes.
- ◆ **Educate patients and caregivers.** Provide education to patients and caregivers regarding proper use of an oral syringe (or other measuring device). Demonstrate how to measure and administer the dose and inform them about how to clean the device, if it is to be reused. Several years ago, Becton Dickinson voluntarily elected to package parenteral syringes without the small caps in response to this serious issue. However, since some manufacturers still include a cap on parenteral syringes, the danger of asphyxiation with the cap is still present. We have again contacted FDA to alert them about this problem. They have stated that they will be following up with each syringe manufacturer with the goal to get the syringe caps removed. At the very minimum, we believe that the packaging of parenteral syringes should be required to clearly state, "not for oral use" or "not for use with oral liquids."

New FDA Web Page Warns Against Buying Isotretinoin Online

FDA has launched a special Web page to warn consumers about the dangers of buying isotretinoin online. Improperly used, isotretinoin can cause severe side effects, including birth defects and serious mental health problems. The Web page, www.fda.gov/buyonline/accutane, is positioned as a search result on Internet search engines when consumers initiate an online search for the drug under any one of its four names (isotretinoin is sold under the brand name of Accutane® and in generic versions called

Amnesteem™, Claravis™, and Sotret®). The Web page warns that the drug "should only be taken under the close supervision" of a physician and a pharmacist, and provides links to related information, including ways to check that drugs purchased online come from legitimate pharmacies.

To reduce risks, FDA and the manufacturers of isotretinoin have implemented a strict distribution program called iPLEDGE to ensure that women using isotretinoin do not become pregnant, and that women who are pregnant do not use isotretinoin. Isotretinoin is available only at pharmacies that are registered for this distribution program. Additionally, the distribution program is designed to prevent the sale of isotretinoin over the Internet. Dispensing must comply with the agency's risk management requirements.

Tampering Results in Misbranding of Ziagen as Combivir

GlaxoSmithKline and FDA warned health care professionals of an apparent third-party tampering that resulted in the misbranding of Ziagen® as Combivir® and employed counterfeit labels for Combivir tablets. Two 60-count misbranded bottles of Combivir tablets contained 300 mg tablets of Ziagen.

The counterfeit labels identified are Lot No. 6ZP9760 with expiration dates of April 2010 and April 2009. The incident appears to be isolated and limited in scope to one pharmacy in California.

Pharmacists are advised to immediately examine the contents of each bottle of Combivir in their pharmacies to confirm that the bottles contain the correct medication. If a bottle contains anything other than Combivir tablets, pharmacists are advised to notify the manufacturer.

The letter from GlaxoSmithKline and FDA, containing photos of actual Combivir and Ziagen tablets, is posted on the FDA Web site at www.fda.gov/medwatch/safety/2007/Ziagen_Dear_RPh_03-29-2007.pdf.

FDA Issues Halt on Manufacture, Distribution of Unapproved Suppository Drugs

FDA notified health care professionals and consumers that companies must stop manufacturing and distributing unapproved suppository drug products containing trimethobenzamide hydrochloride.

These products, used to treat nausea and vomiting in adults and children, have been marketed under various names, including Tigan®, Tebamide™, T-Gen, Trimazide, and Trimethobenz. Drugs containing trimethobenzamide in suppository form lack evidence of effectiveness. This action does not affect oral capsules and injectable products containing trimethobenzamide that have been approved by FDA.

FDA urges consumers currently using trimethobenzamide suppositories or who have questions or concerns to contact their health care professionals. Alternative products approved to effectively treat nausea and vomiting are available in a variety of forms.

The MedWatch safety summary and a link to the full press release are available at www.fda.gov/medwatch/safety/2007/safety07.htm#trimethobenzamide.

Continued from page 1

physician in the state of Missouri, and did not tell health care professionals of his chemical dependency. Section 338.055.2(1) (5) (6) (13) (15) and (17), RSMo 2000.

Richard E. Hoatson #041101, Kansas City, MO. May 25, 2007. Pharmacist license placed on probation for five (5) years. Made unsolicited sexual overtures to a fellow employee; exposed his genitalia to a fellow employee. Section 338.055.2(5) for misconduct and (13).

Shawn P. Reidy #041667, Overland Park, KS. March 29, 2007. Pharmacist license revoked, cannot reapply for seven (7) years. Second violation of previous discipline. Tested positive for alcohol in drug screen, failed to fully comply with drug testing requirement of probation order, failed to complete an alcohol/drug abuse counseling program as required. Section 338.055.2(6) and (13).

Walter E. Sewell #042679, Saint Joseph, MO. March 25, 2007. Pharmacist license revoked; cannot reapply for licensure for seven years. Pled guilty in a criminal case to felony publishing child pornography and felony distributing child pornography. Section 338.065.

Erick R. Stephenson #2004005629, Imperial, MO. March 28, 2007. Pharmacist license censured. Dispensed opium 10% tincture deodorized instead of tincture of camphorated opium as prescribed for a 12-month-old patient and failed to provide proper counseling to the parent of that patient. Section 338.055.2(5) and (6) RSMo 2000.

Cheryl A. Wagoner #045119, Saint Louis, MO. May 25, 2007. Pharmacist license placed on probation for five (5) years. Failed to fulfill her responsibilities as a pharmacist-in-charge, demonstrated a conscious indifference to professional duty to comply with the laws and regulations governing the practice of pharmacy, violated a relationship of professional trust and confidence with co-workers and patients. Section 338.055.2(6) and (13) RSMo Cum. Supp. 2004.

David G. Younker #040072, Monett, MO. March 26, 2007. Pharmacist license revoked; cannot reapply for licensure for seven (7) years. Pled guilty in a criminal case to felony charges of trafficking in drugs in the first degree (four counts); distributing drugs near schools, unlawful use of drug paraphernalia, and keeping or maintaining a public nuisance. Section 338.065.

Drug Distributors

Interstate Imaging #2006008535 – Earth City, MO. April 11, 2007. Permanent drug distributor license placed on probation for three (3) years. Failed to timely renew drug distributor license, continued to operate as a drug distributor without proper licensure, failed to maintain required humidity and alarm systems or have an exemption from same, failed to maintain a temperature control log. Section 338.055.1 and .2(5), (6), (10), (13) and (15) RSMo Cum. Supp. 2006

Teleflex Medical Distribution Center #2006035184 – Haslet (Fort Worth) TX. April 12, 2007. Restricted Drug Distributor license placed on probation for three (3) years. Distributed legend drug-related devices into the state of Missouri without first obtaining license to do so. Section 338.055.1 and .1(5)(6) and (15) RSMo

Xttrium Laboratories, Inc #2005006347 – Chicago, IL. June 27, 2007. Drug Distributor Registration placed on probation for three (3) years. Repeatedly shipped legend drugs and/or medical devices into the state of Missouri without being properly licensed; violated the professional trust and confidence with patients and prescribers; failed to fully meet Food and Drug Administration manufacturing standards. Section 338.055.1 and .2 (5), (13) and (15).

Page 4 – August 2007

The *Missouri Board of Pharmacy News* is published by the Missouri Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote voluntary compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of the Foundation or the Board unless expressly so stated.

Matt Blunt - Governor

Douglas M. Ommen - Department Director

David Broeker - Division Director

Debra C. Ringgenberg, RPh - State News Editor

Carmen A. Catizone, MS, RPh, DPh - National News Editor
& Executive Editor

Larissa Doucette - Editorial Manager

Presorted Standard
U.S. Postage
PAID
Chicago, Illinois
Permit No. 5744

MISSOURI BOARD OF PHARMACY

National Association of Boards of Pharmacy Foundation, Inc
1600 Feehanville Drive
Mount Prospect, IL 60056